# Supplementary Information

**Table S1. Mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ).**

Key to scoring: 0, not troubled; 1, hardly troubled at all; 2, somewhat troubled; 3, moderately troubled; 4, quite a bit troubled; 5, very troubled; 6, extremely troubled.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Domains and items** | **Score** | | | | | | |
| *Activity limitations* |  | | | | | | |
| 1. Regular activities at home and work  (your occupation or tasks that you have to do regularly around your home and/or garden) | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Recreational activities (indoor and outdoor activities with friends and family, sports, social activities, hobbies | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Sleep (difficulties getting a good night’s sleep and/or getting to sleep at night) | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| *Practical problems* |  |  |  |  |  |  |  |
| 1. Need to rub nose/eyes | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Need to blow nose repeatedly | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| *Nasal symptoms* |  |  |  |  |  |  |  |
| 1. Sneezing | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Stuffy blocked nose | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Runny nose | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| *Eye symptoms* |  |  |  |  |  |  |  |
| 1. Itchy eyes | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Sore eyes | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Watery eyes | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| *Other symptoms* |  |  |  |  |  |  |  |
| 1. Tiredness and/or fatigue | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Thirst | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
| 1. Feeling irritable | 0 | 1 | 2 | 3 | 4 | 5 | 6 |

**Table S2. Change from baseline in least-squares mean miniRQLQ scores, both overall and for individual domains, in patients with concomitant allergic conjunctivitis. Data in brackets show 95% confidence intervals.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **TAA (*n*=37)** | | **FP (*n*=43)** | | **p** |
| **Overall miniRQLQ score** |  |  |  |  |  |
| Week 1 | –12.78 (–16.80, –8.78) | p <0.001 | –13.74 (–17.47, –10.02) | p <0.001 | 1.0000 |
| Week 2 | –22.70 (–26.72, –18.69) | p <0.001 | –18.67 (–22.40, –14.95) | p <0.001 | 0.8304 |
| Week 3 | –29.49 (–33.50, –25.48) | p <0.001 | –27.72 (–31.44, –24.00) | p <0.001 | 0.9983 |
| Week 4 | –34.84 (–38.85, –30.83) | p <0.001 | –33.02 (–36.74, –29.30) | p <0.001 | 0.9980 |
| **Activity limitations** |  |  |  |  |  |
| Week 1 | –2.38 (–3.36, –1.40) | p <0.001 | –2.77 (–3.68, –1.86) | p <0.001 | 0.9991 |
| Week 2 | –4.95 (–5.93, –3.96) | p <0.001 | –4.09 (–5.01, –3.18) | p <0.001 | 0.9135 |
| Week 3 | –6.46 (–7.44, –5.48) | p <0.001 | –6.12 (–7.03, –5.20) | p <0.001 | 0.9996 |
| Week 4 | –7.51 (–8.50, –6.53) | p <0.001 | –7.42 (–8.33, –6.51) | p <0.001 | 1.0000 |
| **Practical problems** |  |  |  |  |  |
| Week 1 | –1.89 (–2.64, –1.14) | p <0.001 | –1.84 (–2.54, –1.14) | p <0.001 | 1.0000 |
| Week 2 | –3.43 (–4.19, –2.68) | p <0.001 | –2.40 (–3.09, –1.70) | p <0.001 | 0.4851 |
| Week 3 | –4.46 (–5.21, –3.71) | p <0.001 | –3.93 (–4.63, –3.23) | p <0.001 | 0.9711 |
| Week 4 | –5.16 (–5.91, –4.41) | p <0.001 | –5.02 (–5.72, –4.33) | p <0.001 | 1.0000 |
| **Nasal symptoms** |  |  |  |  |  |
| Week 1 | –3.38 (–4.50, –2.26) | p <0.001 | –3.28 (–4.32, –2.24) | p <0.001 | 1.0000 |
| Week 2 | –5.49 (–6.61, –4.37) | p <0.001 | –4.23 (–5.27, –3.20) | p <0.001 | 0.7345 |
| Week 3 | –6.81 (–7.93, –5.69) | p <0.001 | –6.33 (–7.36, –5.29) | p <0.001 | 0.9984 |
| Week 4 | –8.16 (–9.28, –7.04) | p <0.001 | –7.56 (–8.60, –6.52) | p <0.001 | 0.9939 |
| **Eye symptoms** |  |  |  |  |  |
| Week 1 | –2.14 (–3.19, –1.08) | p <0.001 | –2.61 (–3.58, –1.63) | p <0.001 | 0.9982 |
| Week 2 | –3.46 (–4.51, –2.41) | p <0.001 | –3.61 (–4.58, –2.63) | p <0.001 | 1.0000 |
| Week 3 | –5.30 (–6.35, –4.24) | p <0.001 | –5.12 (–6.09, –4.14) | p <0.001 | 1.0000 |
| Week 4 | –6.51 (–7.57, –5.46) | p <0.001 | –6.02 (–7.00, –5.05) | p <0.001 | 0.9976 |
| **Other symptoms** |  |  |  |  |  |
| Week 1 | –3.00 (–4.18, –1.83) | p <0.001 | –3.26 (–4.35, –2.17) | p <0.001 | 1.0000 |
| Week 2 | –5.38 (–6.55, –4.20) | p <0.001 | –4.35 (–5.44, –3.26) | p <0.001 | 0.9092 |
| Week 3 | –6.46 (–7.64, –5.28) | p <0.001 | –6.23 (–7.32, –5.14) | p <0.001 | 1.0000 |
| Week 4 | –7.49 (–8.66, –6.31) | p <0.001 | –7.00 (–8.09, –5.91) | p <0.001 | 0.9989 |

*Patient and physician satisfaction with therapy after 28-days treatment*

Global Satisfaction Assessment:

Patient and physician satisfaction was evaluated after 28 days of treatment by the global satisfaction assessment 5-point scale; 0 - substantial deterioration, 1 -little deterioration, 2 - no change, 3 - little improvement, 4 - substantial improvement

**Table S3. Patient and physician satisfaction with therapy after 28-days treatment**

|  |  |  |
| --- | --- | --- |
|  | **Triamcinolone Acetonide** | **Fluticasone Propionate** |
|  | **(n=128)** | **(n=128)** |
| **Patient Satisfaction** |  |  |
| 0 - substantial deterioration | 0 (0.0%) | 0 (0.0%) |
| 1 - little deterioration | 0 (0.0%) | 0 (0.0%) |
| 2 - no change | 2 (1.6%) | 0 (0.0%) |
| 3 - little improvement | 19 (14.8%) | 16 (12.5%) |
| 4 - substantial improvement | 107 (83.6%) | 112 (87.5%) |
| **Physician satisfaction** |  |  |
| 0 - substantial deterioration | 0 (0.0%) | 0 (0.0%) |
| 1 - little deterioration | 0 (0.0%) | 0 (0.0%) |
| 2 - no change | 1 (0.8%) | 0 (0.0%) |
| 3 - little improvement | 19 (14.8%) | 11 (8.6%) |
| 4 - substantial improvement | 108 (84.4%) | 117 (91.4%) |